MD1171Z - Method for treating the decellularized liver matrix to enhance cell adhesion - Google Patents
Method for treating the decellularized liver matrix to enhance cell adhesion Download PDFInfo
- Publication number
- MD1171Z MD1171Z MDS20160156A MDS20160156A MD1171Z MD 1171 Z MD1171 Z MD 1171Z MD S20160156 A MDS20160156 A MD S20160156A MD S20160156 A MDS20160156 A MD S20160156A MD 1171 Z MD1171 Z MD 1171Z
- Authority
- MD
- Moldova
- Prior art keywords
- liver
- matrix
- decellularized
- decellularized liver
- amount
- Prior art date
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 31
- 239000011159 matrix material Substances 0.000 title claims abstract description 21
- 230000021164 cell adhesion Effects 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 18
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims abstract description 8
- 241000283690 Bos taurus Species 0.000 claims abstract description 6
- 102000012422 Collagen Type I Human genes 0.000 claims abstract description 6
- 108010022452 Collagen Type I Proteins 0.000 claims abstract description 6
- 210000001361 achilles tendon Anatomy 0.000 claims abstract description 6
- 210000003240 portal vein Anatomy 0.000 claims abstract description 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims abstract description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims abstract description 4
- 229960003942 amphotericin b Drugs 0.000 claims abstract description 4
- 229960005322 streptomycin Drugs 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 11
- 230000002440 hepatic effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 2
- 230000001172 regenerating effect Effects 0.000 abstract description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 2
- 239000002953 phosphate buffered saline Substances 0.000 abstract 2
- 229930182555 Penicillin Natural products 0.000 abstract 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 1
- 229940049954 penicillin Drugs 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
Invenţia se referă la medicina regenerativă şi ingineria tisulară şi poate fi utilizată pentru prelucrarea matricei decelularizate a ficatului pentru sporirea adeziunii celulare. The invention relates to regenerative medicine and tissue engineering and can be used for processing decellularized liver matrix to enhance cell adhesion.
Cu aceeaşi destinaţie, în condiţii de laborator matricea decelularizată a unui lob al ficatului este recelularizată cu câte 1,5x107 hepatocite la fiecare 10 min până se ajunge la 2x108 celule [1]. În timpul procesului de recelularizare nu se utilizează suplimentar nici o substanţă pentru mărirea aderării celulelor la matricea extracelulară a ficatului decelularizat. For the same purpose, under laboratory conditions the decellularized matrix of a liver lobe is recellularized with 1.5x107 hepatocytes every 10 min until 2x108 cells are reached [1]. During the recellularization process, no additional substance is used to increase cell adhesion to the extracellular matrix of the decellularized liver.
Dezavantajul constă în aceea că în timpul procesului de recelularizare are loc pierderea excesivă de hepatocite din cauza adeziunii insuficiente a hepatocitelor injectate de matricea hepatică decelularizată. The disadvantage is that during the recellularization process, excessive hepatocyte loss occurs due to insufficient adhesion of the injected hepatocytes to the decellularized hepatic matrix.
Problema pe care o rezolvă invenţia constă în utilizarea unei metode noi, ce ar permite amplificarea adeziunii hepatocitelor de matricea decelularizată a ficatului şi ar împiedica pierderea lor excesivă după injectare. The problem solved by the invention consists in using a new method, which would allow the amplification of hepatocyte adhesion to the decellularized liver matrix and would prevent their excessive loss after injection.
Esenţa invenţiei constă în aceea că se spală matricea decelularizată a ficatului prin injectarea în vena portă a unui amestec de soluţie tampon fosfat salin, streptomicină 100 µg/ml, penicilină 100 U/ml şi amfotericină B 0,25 µg/ml, în cantitate de 20 ml/10 g de ficat decelularizat, apoi se injectează soluţie de colagen tip I, obţinut din tendonul Achile de bovină în concentraţie de 0,01%, dizolvat în 0,1M de acid acetic, în cantitate de 160...240 ml/10 g de ficat decelularizat, după care matricea hepatică se perfuzează cu soluţie tampon fosfat salin cu un pH 7,4 în cantitate de 300 ml/10 g de ficat cu o viteză de 5 ml/min. The essence of the invention consists in washing the decellularized liver matrix by injecting into the portal vein a mixture of phosphate buffer saline, streptomycin 100 µg/ml, penicillin 100 U/ml and amphotericin B 0.25 µg/ml, in an amount of 20 ml/10 g of decellularized liver, then injecting a solution of type I collagen, obtained from bovine Achilles tendon in a concentration of 0.01%, dissolved in 0.1M acetic acid, in an amount of 160...240 ml/10 g of decellularized liver, after which the liver matrix is perfused with phosphate buffer saline with a pH of 7.4 in an amount of 300 ml/10 g of liver at a rate of 5 ml/min.
Avantajele metodei revendicate constau în aceea că este simplă, economă şi eficientă. Metoda propusă ameliorează şi majorează viteza procesului de recelularizare a ficatului prin sporirea adeziunii matricei extracelulare hepatice. The advantages of the claimed method are that it is simple, economical and efficient. The proposed method improves and increases the speed of the liver recellularization process by increasing the adhesion of the hepatic extracellular matrix.
Rezultatul constă în aceea că respectiva metodă - eficientă, sigură, economă şi uşor de implementat, permite o adeziune mai rapidă, evitându-se pierderi excesive de hepatocite injectate în matricea hepatică decelularizată în timpul procesului de recelularizare. The result is that the method - efficient, safe, economical and easy to implement - allows for faster adhesion, avoiding excessive losses of hepatocytes injected into the decellularized hepatic matrix during the recellularization process.
În scopul creşterii adeziunii hepatocitelor de matricea extracelulară a ficatului decelularizat şi evitării pierderii lor excesive, s-a utilizat soluţie de colagen tip I obţinut din tendon Achile de bovină cu o concentraţie de 0,01% dizolvat în 0,1 M de acid acetic, care se injectează foarte încet în matricea hepatică decelularizată prin vena portă. In order to increase the adhesion of hepatocytes to the extracellular matrix of the decellularized liver and avoid their excessive loss, a solution of type I collagen obtained from bovine Achilles tendon with a concentration of 0.01% dissolved in 0.1 M acetic acid was used, which was injected very slowly into the decellularized hepatic matrix through the portal vein.
Modalitatea de creştere a adeziunii hepatocitelor de matricea extracelulară a ficatului decelularizat constă în injectarea soluţiei colagen tip I obţinut din tendon Achile de bovină, cu concentraţia de 0,01% dizolvat în 0,1 M de acid acetic, după o spălare prealabilă cu soluţie PBS şi un compus antibiotic-antimicotic (streptomicină 100 µg/ml, penicilină 100 U/ml, amfotericină B 0,25 µg/ml). Cantitatea de soluţie de colagen injectată este direct proporţională cu masa ficatului. La 10 g de masă umedă de ficat se utilizează 200 ml ±40 ml de soluţie de colagen, acesta se injectează foarte lent pentru a permite ataşarea fibrelor de colagen de matricea hepatică decelularizată evitând formarea conglomeratelor şi obturarea vaselor intrahepatice. Pentru a verifica dacă vasele matricei decelularizate nu sunt obturate de fibrele de colagen şi a aduce pH-ul la unul normal de 7,2…7,4 pentru a asigura viabilitatea celulelor, matricea hepatică se perfuzează cu PBS în volum de 300 ml/10 g ficat decelularizat, cu o viteză de 5 ml/min şi un pH egal cu 7,4. Totodată se urmăreşte umplerea şi extravazarea uniformă a lichidului din matricea hepatică decelularizată. The method of increasing the adhesion of hepatocytes to the extracellular matrix of the decellularized liver consists of injecting a solution of type I collagen obtained from bovine Achilles tendon, with a concentration of 0.01% dissolved in 0.1 M acetic acid, after a prior wash with PBS solution and an antibiotic-antimycotic compound (streptomycin 100 µg/ml, penicillin 100 U/ml, amphotericin B 0.25 µg/ml). The amount of collagen solution injected is directly proportional to the mass of the liver. For 10 g of wet mass of liver, 200 ml ± 40 ml of collagen solution is used, it is injected very slowly to allow the attachment of collagen fibers to the decellularized hepatic matrix, avoiding the formation of conglomerates and the obstruction of intrahepatic vessels. To verify that the vessels of the decellularized matrix are not clogged by collagen fibers and to bring the pH to a normal one of 7.2…7.4 to ensure cell viability, the liver matrix is perfused with PBS in a volume of 300 ml/10 g of decellularized liver, at a rate of 5 ml/min and a pH equal to 7.4. At the same time, the uniform filling and extravasation of the fluid from the decellularized liver matrix is monitored.
Exemplu Example
Prin vena portă matricea extraxelulară a 10 g de ficat decelularizat se spală cu 20 ml soluţie PBS şi antibiotic antimicotic. Apoi cu viteza de 1 ml/min se injectează 200 ml de soluţie de colagen tip I de 0,01%, obţinut din tendon Achile de bovină dizolvat în acid acetic de 0,1 M. Ulterior, matricea decelularizată se spală cu o viteză de 5 ml/min cu 300 ml soluţie PBS cu pH-ul de 7,4. Through the portal vein, the extracellular matrix of 10 g of decellularized liver is washed with 20 ml of PBS solution and antifungal antibiotic. Then, at a rate of 1 ml/min, 200 ml of 0.01% type I collagen solution, obtained from bovine Achilles tendon dissolved in 0.1 M acetic acid, is injected. Subsequently, the decellularized matrix is washed at a rate of 5 ml/min with 300 ml of PBS solution with pH 7.4.
Metoda corespunde cerinţelor şi normelor sanitare, necesită utilizarea soluţiei de colagen de 0,01% şi a matricei hepatice decelularizate şi se efectuează în condiţii sterile. The method complies with sanitary requirements and norms, requires the use of 0.01% collagen solution and decellularized liver matrix and is performed under sterile conditions.
Această metodă se utilizează pentru mărirea adeziunii hepatocitelor în timpul recelularizării ficatului decelularizat în cadrul Laboratorului de Inginerie Tisulară şi Culturi Celulare. This method is used to increase hepatocyte adhesion during recellularization of decellularized liver within the Tissue Engineering and Cell Culture Laboratory.
1. Uygun B., Price G., Saeidi N., Izamis M., Berendsen T., Yarmush M., Uygun K. Decellularization and Recellularization of Whole Livers. JoVE, 48, 2011. http://www.jove.com/details.php?id=2394 1. Uygun B., Price G., Saeidi N., Izamis M., Berendsen T., Yarmush M., Uygun K. Decellularization and Recellularization of Whole Livers. JoVE, 48, 2011. http://www.jove.com/details.php?id=2394
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20160156A MD1171Z (en) | 2016-12-23 | 2016-12-23 | Method for treating the decellularized liver matrix to enhance cell adhesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20160156A MD1171Z (en) | 2016-12-23 | 2016-12-23 | Method for treating the decellularized liver matrix to enhance cell adhesion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1171Y MD1171Y (en) | 2017-07-31 |
| MD1171Z true MD1171Z (en) | 2018-02-28 |
Family
ID=59383904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20160156A MD1171Z (en) | 2016-12-23 | 2016-12-23 | Method for treating the decellularized liver matrix to enhance cell adhesion |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1171Z (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU952958A1 (en) * | 1980-08-01 | 1982-08-23 | Институт проблем онкологии им.Р.Е.Кавецкого | Method for preparing isolated liver cells |
| SU1053803A1 (en) * | 1981-11-05 | 1983-11-15 | 2-Й Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова | Method of preserving isolated liver cells |
| SU1289437A1 (en) * | 1984-08-20 | 1987-02-15 | Казахский научно-исследовательский институт клинической и экспериментальной хирургии им.А.Н.Сызганова | Method of preserving isolated cells of liver |
| SU1310426A1 (en) * | 1985-06-17 | 1987-05-15 | Институт проблем криобиологии и криомедицины АН УССР | Method for producing isolated cells of liver |
| SU1463757A1 (en) * | 1987-04-02 | 1989-03-07 | Институт проблем криобиологии и криомедицины АН УССР | Method of producing isolated cells of liver |
| SU1513390A1 (en) * | 1987-10-28 | 1989-10-07 | Тюменский государственный медицинский институт | Method of investigating liver cells |
| SU1564550A1 (en) * | 1986-02-06 | 1990-05-15 | Харьковский научно-исследовательский институт терапии | Method of isolating cells from liver and myocardium |
| SU1578192A1 (en) * | 1988-04-26 | 1990-07-15 | Институт проблем онкологии им.Р.Е.Кавецкого | Method of growing cells of liver |
| SU1673969A1 (en) * | 1986-04-08 | 1991-08-30 | Научно-исследовательский институт физико-химической медицины | Method for production of suspension for reconstruction of liver membranes and cells |
| MD1015Y (en) * | 2015-05-12 | 2016-03-31 | Ip Universitatea De Stat De Medicină Şi Farmacie "Nicolae Testemiţanu" Din Republica Moldova | Method for decellularization of liver in experimental animals |
-
2016
- 2016-12-23 MD MDS20160156A patent/MD1171Z/en not_active IP Right Cessation
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU952958A1 (en) * | 1980-08-01 | 1982-08-23 | Институт проблем онкологии им.Р.Е.Кавецкого | Method for preparing isolated liver cells |
| SU1053803A1 (en) * | 1981-11-05 | 1983-11-15 | 2-Й Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова | Method of preserving isolated liver cells |
| SU1289437A1 (en) * | 1984-08-20 | 1987-02-15 | Казахский научно-исследовательский институт клинической и экспериментальной хирургии им.А.Н.Сызганова | Method of preserving isolated cells of liver |
| SU1310426A1 (en) * | 1985-06-17 | 1987-05-15 | Институт проблем криобиологии и криомедицины АН УССР | Method for producing isolated cells of liver |
| SU1564550A1 (en) * | 1986-02-06 | 1990-05-15 | Харьковский научно-исследовательский институт терапии | Method of isolating cells from liver and myocardium |
| SU1673969A1 (en) * | 1986-04-08 | 1991-08-30 | Научно-исследовательский институт физико-химической медицины | Method for production of suspension for reconstruction of liver membranes and cells |
| SU1463757A1 (en) * | 1987-04-02 | 1989-03-07 | Институт проблем криобиологии и криомедицины АН УССР | Method of producing isolated cells of liver |
| SU1513390A1 (en) * | 1987-10-28 | 1989-10-07 | Тюменский государственный медицинский институт | Method of investigating liver cells |
| SU1578192A1 (en) * | 1988-04-26 | 1990-07-15 | Институт проблем онкологии им.Р.Е.Кавецкого | Method of growing cells of liver |
| MD1015Y (en) * | 2015-05-12 | 2016-03-31 | Ip Universitatea De Stat De Medicină Şi Farmacie "Nicolae Testemiţanu" Din Republica Moldova | Method for decellularization of liver in experimental animals |
Non-Patent Citations (1)
| Title |
|---|
| Uygun B., Price G., Saeidi N., Izamis M., Berendsen T., Yarmush M., Uygun K. Decellularization and Recellularization of Whole Livers. JoVE, 48, 2011. http://www.jove.com/details.php?id=2394 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD1171Y (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nascimento et al. | Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms | |
| Gao et al. | The use of chitosan based hydrogel for enhancing the therapeutic benefits of adipose-derived MSCs for acute kidney injury | |
| Tao et al. | Proangiogenic features of mesenchymal stem cells and their therapeutic applications | |
| Jha et al. | Enhanced survival and engraftment of transplanted stem cells using growth factor sequestering hydrogels | |
| Han et al. | Co-transplantation of exosomes derived from hypoxia-preconditioned adipose mesenchymal stem cells promotes neovascularization and graft survival in fat grafting | |
| Wang et al. | Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium | |
| Rustad et al. | Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold | |
| Park et al. | Human umbilical cord blood-derived mesenchymal stem cells prevent diabetic renal injury through paracrine action | |
| Xinaris et al. | In vivo maturation of functional renal organoids formed from embryonic cell suspensions | |
| O’Loughlin et al. | Topical administration of allogeneic mesenchymal stromal cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer | |
| Zhang et al. | Autophagy mediates the beneficial effect of hypoxic preconditioning on bone marrow mesenchymal stem cells for the therapy of myocardial infarction | |
| Wu et al. | The roles of mesenchymal stem cells in tissue repair and disease modification | |
| Zhang et al. | Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis | |
| Aggarwal et al. | Concise review: stem/progenitor cells for renal tissue repair: current knowledge and perspectives | |
| Xu et al. | hiPS-MSCs differentiation towards fibroblasts on a 3D ECM mimicking scaffold | |
| Saito et al. | Homing effect of adipose‐derived stem cells to the injured liver: the shift of stromal cell‐derived factor 1 expressions | |
| Chen et al. | Sphingosine 1-phosphate promotes mesenchymal stem cell-mediated cardioprotection against myocardial infarction via ERK1/2-MMP-9 and Akt signaling axis | |
| Gomzikova et al. | Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells | |
| Jia et al. | Bone marrow mesenchymal stromal cells ameliorate angiogenesis and renal damage via promoting PI3k-Akt signaling pathway activation in vivo | |
| HUE026292T2 (en) | Microvesicles (mvs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease | |
| Mayhew et al. | Tumor dormancy in bone | |
| Shou et al. | Enhancement of bone‐marrow‐derived mesenchymal stem cell angiogenic capacity by NPWT for a combinatorial therapy to promote wound healing with large defect | |
| Jadczyk et al. | Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology | |
| Zhao et al. | Human amniotic epithelial cells attenuate TGF-β1-induced human dermal fibroblast transformation to myofibroblasts via TGF-β1/Smad3 pathway | |
| Gottipati et al. | Gelatin based polymer cell coating improves bone marrow-derived cell retention in the heart after myocardial infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |